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Abstract
Purpose Colorectal cancer (CRC) diagnosis reduces life
expectancy and decreases patients’ well-being. We sought
to assess the determinants of health and functional status
and estimate the proportion of remaining life that CRC
survivors would spend in good health.
Methods Using Sullivan method, healthy life expectancy
was calculated based on survival data of 14,849 CRC
survivors within a population-based cancer registry in
southern Netherlands and quality of life information among
a random sample of these survivors (n = 1,291).
Results Overall, albeit short life expectancy (LE at age
50 = 12 years for males and 13 years for females), most
CRC survivors spent a large proportion of their remaining
life in good health (74 and 77 %, for males and females,
respectively). Long-term survivors may expect to live a
normal life span (LE at age 50 = 30 years) and spent a
large proportion of the remaining life in good health
(78 %). In distinction, those with stage IV CRC had less
than 2 years to live and spent more than half of their
remaining life in poor health.
Conclusions Most CRC patients may expect no com-
promise on living a healthy life, underlining the importance
of early detection. On the other hand, the high proportion
of non-healthy years among stage IV CRC survivors con-
firms the importance of early detection and palliative care.
Keywords Colorectal cancer  Healthy life expectancy 
Population-based  Survivors
Introduction
Due to increased awareness of colorectal cancer (CRC)
resulting in earlier detection and improvement in treatment,
survival among CRC patients has been increasing [1]. Quality
of life (QoL) among patients in the first 3 years after diagnosis
is generally decreased, although it may improve with time since
diagnosis [2]. Yet, many CRC survivors continue to live with
long-term side effects of having had the cancer [3], especially
related to its treatment. In the last decade, treatment for CRC
has become more aggressive. It now includes new chemo-
therapy agents and combinations of agents, and new radiation
and surgical approaches [4] for patients with both curable and
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incurable disease at the time of diagnosis. While these advances
in treatment have been associated with increasing rates of
survival, they are also associated with increasing rates of long-
term side effects such as fatigue, gastrointestinal problems,
urinary incontinence, and sexual dysfunction [4]. These side
effects can be quite serious, aggravated by the fact that CRC
survivors are generally older and commonly have other coex-
isting chronic diseases [5]. Besides physical discomfort, CRC
also impacts psychologically on the patient, that is, fear of
recurrence, anxiety, depression or negative body image which
may lower quality of life [4, 6].
In this study, we determined the factors associated with
self-reported health and physical functioning after CRC
diagnosis using population-based data. This result was used
to calculate the proportion of healthy life expectancy and
disability-free life expectancy to be compared to that of the
general Dutch population. Estimating the proportion of
healthy life years is an innovative approach in oncological
research and may serve as a tool to assess the level of cure
among survivors not only by estimating survival but
incorporating available information on survivors’ well-
being and functional abilities. At the same time, it also
detects groups with poor health state in need of extra care.
Materials and methods
Data
For the analyses, we used data of CRC survivors from the
population-based Eindhoven Cancer Registry (ECR). The ECR
records data of all newly diagnosed cancer cases in the southern
of the Netherlands, an area with 2.4 million inhabitants [7]. The
coverage area of the registry in the south of the Netherlands has
gradually increased, covering about 0.9 million people in 1975
and over 2 million people since 1988. For all cancer patients,
information on tumor stage at diagnosis (based on pathological
and clinical tumor node metastasis (TNM) classified according
to the UICC system [8]), type of primary treatment (type of
surgery, chemotherapy, hormonal therapy, and radiotherapy),
and comorbidity (collected since 1993) is routinely collected.
Furthermore, age, sex, and socioeconomic class (based on zip
codes, collected since 1983) [9] are registered.
Using the Dutch version of the SF-36 [10], QoL assessment
was done in 2009 through postal questionnaires among a ran-
dom sample of 1,692 CRC survivors (response rate 82 %)
within the ECR [11, 12]. These survivors were diagnosed with
CRC between 1998 and 2007. Medical specialists sent their
(former) patients a letter to inform them about the study,
together with the questionnaire. A reminder was sent if the
questionnaire was not returned within 2 months. Approval for
this study was obtained from a local certified Medical Ethics
Committee.
Analyses
We performed a multivariate logistic regression to assess the
association of self-reported health and functional disability
with clinical history. We adjusted for demographic factors
such as gender, age (5-year age groups, and 85 years and over
age group), and socioeconomic class: high, middle, low, and
institutionalized (the later was excluded from further analysis
due to low numbers). For clinical factors, we included subtype
(colon and rectum), pathological staging (pTNM: I, II, III, and
IV, 4 % unknown stage was excluded), treatment (surgery
only, surgery with chemotherapy (high risk colon cancer stage
II and all stage III [13]), and surgery with radiotherapy with or
without chemotherapy (rectal cancer stage III [13])), comor-
bidity at diagnosis (none and one or more), and follow-up time
(5 years or less and 6 years or more).
Using the survivorship history combined with the QoL
assessment, we calculated healthy life expectancy (HLE)
and disability-free life expectancy (DFLE). This calculation
was only performed for the factors that influenced well-being
or functional limitation as tested by the multivariate analysis.
First, life expectancy was calculated by building life table
based on the survival history of CRC survivors who were
alive between 2005 and 2009. Data of the most recent five
calendar years were used to ensure sufficient number of
deaths and to have the most recent estimates for life expec-
tancy. For the same reason, we included only data of survi-
vors who were 50 or older at the time of the study. Finally,
life expectancy was calculated based on data of 14,849 sur-
vivors. As for the health status, we used the QoL assessment
of survivors older than 50 years at the time of the survey who
responded to the question on general health (93 % of the total
respondents, n = 1,291) and who answered the question on
mobility limitation (88 % of the total respondents,
n = 1,221). We dichotomized the 5-level answers of the SF-
36 item ‘‘How do you rate your general health?’’ to excellent,
very good and good = good, and fair and poor = poor.
Because one may report good or healthy but have functional
disability, we also included measure of daily functional
ability from the SF-36 in our analysis. The prevalence of
functional disability was calculated based on the 3-level
answer to the SF-36 item ‘‘Are you limited to walk a few
hundred meters due to your health condition?’’ We assigned
functional limitation to those who answered ‘‘yes, very much
limited’’ and ‘‘yes, a little bit limited.’’ Calculations were
performed using the Sullivan method that accommodates
cross-sectional information of the age-specific prevalence of
general health status [14]. We calculated total and healthy
life expectancies using the guide as suggested by the
European Health Expectancy Monitoring Unit (EHEMU)
[15]. Details of the calculation are presented at Appendix 1
(See online resources). All calculation was done using Stata
11.1 for Windows (StataCorp, Texas, USA).
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Results
Between 2005 and 2009, 14,849 people aged 50 years and
over were alive with history of CRC diagnosis in the ECR
(53 % male, Table 1). Most survivors were 65 years or
older (62 %) and commonly had other chronic illnesses at
the time of diagnosis (63 % among those with known status
of coexisting diseases). Two-thirds of the survivors were
diagnosed with stage I or II CRC and had only surgical
treatment. Five-year survival proportion by stage was
shown in Fig. 1. There is a marked difference in survival
by stage: 57 % of the cases with stage I survived at
10 years compared to 7 % of those with stage IV.
Determinants of poor health and physical disability
Poor health was associated with gender, socioeconomic
status, tumor stage, and coexisting illnesses at diagnosis
(Table 2). The strongest predictor of poor perceived health
was stage. Survivors with stage IV were six times more likely
to report poor health compared to those with stage I. Having
one or more chronic disease at diagnosis was also one of the
strongest predictors of poor health [Odds ratio (OR) = 2.5,
95 % confidence interval (95 % CI) = 1.8–3.4]. Low and
middle socioeconomic class were also positively correlated
with poor health [OR = 2.2 (1.5–3.1) and 1.5 (1.1–2.1),
respectively]. Finally, female survivors were 50 % more
likely to report poor health than males. Types of CRC
treatment did not influence reported general health. If we did
not include stage in the multivariate regression, the odds of
reporting poor general health remained similar for those who
had radiation with or without chemotherapy, increased to 1.1
(95 % CI: 0.8–1.6, from OR: 0.72) among those who had
chemotherapy and to 5.4 (95 % CI: 1.4–20.1, from OR: 1.2)
among those who had other therapy, respectively (results not
shown).
Similar results were observed for functional limitation
(not being able to walk a few hundred meters, Table 3). In
addition, we observed that being diagnosed with stage III
CRC (besides stage IV) was also positively related to
functional disability. Although not significantly related to
perceived health, higher age was related to increasing
functional limitation: CRC survivors aged 80 ? years were
four times more likely to have difficulty in walking a few
hundred meters than those age 50–64 years.
Table 1 Characteristics of living colorectal cancer survivors in
2005–2009
Male (n, %) Female (n, %)
Age at diagnosis
\50 years 371 (5) 312 (4)
50–64 years 2,753 (35) 2,143 (31)
65–79 years 3,899 (50) 3,394 (48)
80 ? years 800 (10) 1,177 (17)
Age at in 2005–2009a
50–64 years 2,329 (30) 1,712 (24)
65–79 years 4,127 (53) 3,423 (49)
80 ? years 1,367 (17) 1,891 (27)
Socioeconomic group
Low 1,725 (22) 1,970 (28)
Middle 3,042 (39) 2,556 (36)
High 2,531 (32) 1,884 (27)
Institutionalized 257 (3) 359 (5)
Missing 268 (3) 257 (4)
Tumor site
Colon 4,731 (60) 4,875 (69)
Rectum 3,092 (40) 2,151 (31)
Stage
I 2,121 (27) 1,763 (25)
II 2,697 (34) 2,587 (37)
III 1,875 (24) 1,784 (25)
IV 1,130 (14) 892 (13)
Treatment
Surgery (S) only 4,321 (55) 4,525 (61)
S ? chemotherapy 1,174 (15) 1,027 (14)
S ? radio- ± chemotherapy 1,729 (22) 1,250 (17)
Other 599 (8) 635 (8)
Comorbidity
0 2,353 (30) 2,239 (32)
1 or more 4,272 (55) 3,537 (50)
Unknown 1,198 (15) 1,250 (18)
Total 7,823 7,026
a This cohort (n = 14,849) was used to build the life table and cal-
culate life expectancy. They were living colorectal cancer cases
(CRC) in the year 2005–2009. These survivors were diagnosed with
CRC between 1975 and 2009 in the catchments’ area of the southern
Netherlands population cancer registry
Fig. 1 Survival proportion among colorectal cancer survivors, alive
between 2000 and 2009
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Healthy life expectancy (HLE) and disability-free life
expectancy (DFLE)
On average, a 50-year-old CRC survivor may live for another
12 years (men) and 13 years (women), with most of their
remaining life spent in good health (77 % in men and 74 % in
women, Table 4). Stage greatly determined life expectancy
and the proportion of life years spent in good health. On the
other hand, although there was no association between fol-
low-up time and health status, long-term survivors, that is,
followed for 6 years or more had a longer life expectancy as
compared to short-term survivors, that is, followed for
5 years or less (life expectancy at 50 were 29.9 vs. 7.5 years,
respectively). A marked difference was also observed
between stage groups for example those diagnosed with
stage I lived on average for another 25–30 years as compared
to 2 years for those with stage IV. In addition, stage IV CRC
survivors also had the shortest portion of remaining life in
good health (47 % for men and 40 % for women). Further-
more, men with stage I–III colorectal spent 76–83 % of their
life after cancer diagnosis without disability compared to
only 53 % for those with stage IV.
From the other prognostic factors, two patterns emerged.
First, groups who lived a larger part of their remaining life
in poor health. This pattern was shown in female of the low
socioeconomic class who could expect to live longer than
Table 2 Perceived health in
colorectal cancer survivors in
2009
Random sample of the
colorectal cancer survivors
within the catchment’s area of
the registry in 2009 (n = 1,291)
a Multivariate analysis adjusted
for sex, age, socioeconomic
status, tumor localization,
period of diagnosis, stage,
comorbidity at diagnosis,
colorectal cancer treatment
Bold value indicates p \ 0.05
Good (n, %) Poor (n, %) Odd ratioa (95 % CI)
for poor health
Sex
Male 561 (59) 169 (51) 1
Female 396 (41) 165 (49) 1.49 (1.14–1.95)
Age at survey
50–64 years 289 (30) 88 (26) 1
65–79 years 551 (58) 181 (54) 0.98 (0.71–1.35)
80 ? years 117 (12) 65 (19) 1.48 (0.96–2.27)
Socioeconomic status
High 367 (38) 86 (26) 1
Middle 366 (38) 126 (38) 1.49 (1.08–2.06)
Low 178 (19) 102 (31) 2.16 (1.51–3.10)
Institutionalized 22 (2) 9 (3) 1.23 (0.51–2.96)
Unknown 24 (2) 11 (3) 1.80 (0.82–3.93)
Tumor site
Colon 632 (66) 224 (67) 1
Rectum 325 (34) 110 (33) 1.24 (0.81–1.90)
Time since diagnosis
B5 years 722 (75) 263 (79) 1
6 ? years 235 (25) 71 (21) 1.05 (0.76–1.45)
Stage at diagnosis
I 270 (28) 97 (29) 1
II 385 (40) 112 (34) 0.77 (0.55–1.08)
III 272 (28) 87 (26) 1.11 (0.72–1.69)
IV 30 (3) 38 (11) 5.76 (2.92–11.38)
Comorbidity at diagnosis
0 415 (43) 86 (26) 1
1 or more 459 (48) 231 (69) 2.47 (1.82–3.35)
Unknown 83 (9) 17 (5) 0.96 (0.53–1.73)
Treatment
Surgery (S) 505 (53) 184 (55) 1
S ? chemotherapy 200 (21) 68 (20) 0.79 (0.49–1.26)
S ? radiotherapy ± chemotherapy 248 (26) 76 (23) 0.72 (0.45–1.14)
Other 4 (0.5) 6 (2) 1.22 (0.25–5.84)
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their male counterpart (12 vs. 9.9 years) but spent 44 % of
their remaining life in poor health (vs. men low socio-
economic class, 35 % in poor health). Another example
was elderly female survivors (80 ? years) who may expect
to live as long as male survivors but would spent 41 and
63 % of their remaining life in poor health and with dis-
ability (vs. male, 31 and 42 %, respectively). Second, those
who lived a long life with large proportion spent in good
health, for example survivors from high socioeconomic
status and those without comorbid disease at diagnosis. On
average, male CRC survivors of high socioeconomic status
may live for another 12.9 years at age 50 and spend 80 %
of it in healthy life (vs. 9.9 years and 65 % among survi-
vors from low socioeconomic).
Discussion
On average, a 50-year-old CRC survivor might live  of
his/her remaining life in good health and without functional
limitation. Being diagnosed with stage IV CRC is the most
important predictor of poor perceived health and functional
disability. Those diagnosed with advanced stage of CRC
had a remarkably low life expectancy and showed a
markedly lower proportion of HLE by spending half of
their remaining life with disability. As for patients with
stage I, II, or III CRC, they reported similar perceived
health, though those with stage III were more likely to
report functional limitation. Other vulnerable groups
included survivors with one or more coexisting disease,
Table 3 Functional disability
(FD) in colorectal cancer
survivors in 2009
Functional disability was
defined as limited to walk a few
hundred meters
Random sample of the
colorectal cancer survivors
within the catchment’s area of
the registry in 2009, 1,221
responded to the question of this
particular outcome
a Multivariate analysis adjusted
for sex, age, socioeconomic
status, tumor localization,
period of diagnosis, stage,
comorbidity at diagnosis,
colorectal cancer treatment
Bold value indicates p \ 0.05
FD 2 (n, %) FD 1 (n, %) Odd ratioa (95 % CI)
for having FD
Sex
Male 488 (59) 203 (52) 1
Female 342 (41) 188 (48) 1.34 (1.03–1.74)
Age at survey
50–64 years 298 (36) 71 (18) 1
65–79 years 454 (55) 235 (60) 2.03 (1.47–2.81)
80 ? years 78 (9) 85 (22) 3.57 (2.30–5.55)
Socioeconomic status
High 339 (41) 91 (23) 1
Middle 320 (39) 145 (37) 1.63 (1.19–2.24)
Low 137 (17) 128 (33) 2.77 (1.94–3.94)
Institutionalized 14 (2) 14 (4) 2.99 (1.30–6.85)
Unknown 20 (2) 13 (3) 2.08 (0.96–4.48)
Tumor site
Colon 540 (65) 275 (70) 1
Rectum 290 (35) 116 (30) 0.91 (0.59–1.42)
Time since diagnosis
B5 years 627 (76) 309 (79) 1
6 ? years 203 (24) 82 (21) 0.98 (0.71–1.35)
Stage at diagnosis
I 247 (30) 99 (25) 1
II 312 (38) 154 (39) 1.20 (0.87–1.67)
III 236 (28) 107 (27) 1.61 (1.05–2.45)
IV 35 (4) 31 (8) 4.14 (2.04–8.39)
Comorbidity at diagnosis
0 372 (45) 101 (26) 1
1 or more 389 (47) 265 (68) 2.10 (1.57–2.81)
Unknown 69 (8) 25 (6) 1.22 (0.72–2.09)
Treatment
Surgery (S) 420 (51) 227 (58) 1
S ? chemotherapy 186 (22) 71 (18) 1.00 (0.61–1.62)
S ? radiotherapy ± chemotherapy 220 (27) 87 (22) 0.64 (0.40–1.00)
Others 4 (0.5) 6 (2) 1.87 (0.38–9.24)
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women especially among the oldest old, and those from the
lowest socioeconomic class.
Study implication
Comparison to general population
CRC survivors had a much lower life expectancy as com-
pared to the general Dutch population (12–13 years in our
cohort vs. 30–34 years in the population) [16]. Yet, it seems
that cure is reached among the long-term survivors as life
expectancy similar to that of the general Dutch population,
confirming results from conditional survival studies [17].
Another good news is that a large proportion of the
remaining life years among survivors were spent in good
health. This is reflected in studies on quality of life among
CRC survivors that have reported good quality of life [2, 6]
and similar physical limitation as the general population [4].
As compared to the Dutch population, CRC survivors spent
even a larger proportion of life after cancer diagnosis in
good health. At age 50, an average Dutch men would spend
66 % (vs. 77 % in survivors) of their remaining life in good
health and Dutch women about 65 % (vs. 74 % in survi-
vors) [18]. One explanation of this finding could be survival
selection. Those who survived cancer are probably the
strongest in the population, thus also having better general
health. Differential in assignment of good or poor health
may also explain the difference. Dutch statistics dichoto-
mized good and very good health into healthy, and those
who responded to general health question as average, fair,
and poor were grouped into not healthy. In our question-
naires, only those who responded fair and poor were
included in the non-healthy group because we did not have
average as a choice of response. Third, this may be also
caused by the non-response: 17 % of the survivors did not
respond to our questionnaires. Though this is a relatively
small number compared to other questionnaires-based
study, nevertheless, non-respondents probably consisted of
mostly those with worse health state [19]. Finally, the
explanation for this difference (lower proportion of HLE
among general population as compared to cancer survivors)
could be the positive attitudes that cancer survivors adopt
after cancer experience, a process which is referred to as
‘‘reframing’’ [20–22].
Table 4 Life expectancy (LE, in years) healthy life expectancy (HLE, in years) and disability-free life expectancy (DFLE) among colorectal
cancer survivors
Men Women
LE, years HLE, years ( %) DFLE, years ( %) LE, years HLE, years ( %) DFLE, years ( %)
Agea
At age 50 12.3 9.5 (77) 9.5 (77) 13.3 9.9 (74) 9.8 (74)
At age 65 9.4 7.3 (77) 6.3 (67) 11.5 7.9 (68) 6.6 (58)
At age 80 5.5 3.8 (69) 3.2 (58) 7.0 4.1 (59) 2.6 (37)
Socioeconomic statusa, b
High 12.5 10.0 (80) 10.2 (82) 14.0 11.8 (79) 11.2 (80)
Middle 13.7 10.9 (80) 10.8 (79) 13.3 9.9 (77) 10.2 (77)
Low 9.3 6.0 (65) 6.3 (68) 12.1 6.5 (56) 6.8 (56)
Time since diagnosisa, b, c
B5 years 7.5 5.6 (74) 6.0 (79) 7.6 5.6 (74) 5.7 (76)
6 ? years 27.6 22.3 (81) 20.8 (75) 32.7 24.5 (75) 22.6 (69)
Stageb
Stage I 25.3 19.1 (75) 19.2 (76) 29.8 21.1 (71) 21.3 (72)
Stage II 19.2 16.0 (83) 14.5 (76) 20.9 15.8 (75) 15.4 (74)
Stage III 13.6 10.7 (79) 11.3 (83) 16.8 12.9 (77) 11.9 (71)
Stage IV 2.1 1.0 (47) 1.1 (53) 2.2 0.9 (40) 1.2 (53)
Comorbiditya, b
0 12.8 10.4 (81) 10.6 (83) 14.8 14.8 (84) 12.2 (82)
1 or more 11.0 7.8 (70) 7.9 (72) 12.5 12.5 (62) 8.5 (66)
a The cohort contributed to 4,721 deaths with a total of 44,139 person years of follow-up (mortality rate of 106 per 10,000)
b Life expectancy at age 50
c Though follow-up time was not related to well-being and functional limitation, we calculated HLE and DLFE because of its relevance to
proportion cured
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Vulnerable groups
A group who had the shortest life span and spent the largest
proportion of their remaining life in ill health was survivors
with stage IV CRC. This finding is in line with other studies
that have indicated lower quality of life among patients with
advanced CRC [2]. The true situation is probably worse
because non-response was highest among those with stage
IV causing underestimation in our estimate [19]. Physiologic
burden from more aggressive and incurable cancer and its
treatment has been suggested as cause of poor quality of life
among these patients. Our findings underline the importance
of early detection and palliative care.
We did not find an association between various treatments
and self-perceived health or functional disability after cor-
rection for observable confounders. In the last few years, new
treatment regimens have been employed on CRC patients.
Because these treatments generally have higher side effects,
we expected some impact on quality of life as compared to
those who only received surgical treatment, especially
among the elderly [5, 23]. Yet, treatment for CRC is largely
determined by the stage of cancer at the presentation of the
disease, making it difficult to disentangle their independent
effect [13]. In a larger cohort within stage difference in
assessing the impact of treatment on quality of life correcting
for other confounders (incl. risk profile) should be done.
Other groups that showed higher likelihood of poor
perceived health and disability with lower proportion of
remaining life in good health were CRC survivors with
comorbidity at diagnosis. Patients with comorbidity were
probably more likely to be smokers or former smokers,
overweight and physically inactive [24], and this might
relate to the generally poor health status. Women aged 80
or older and of the lowest socioeconomic class had also a
low proportion of HLE and DFLE compared to men from
the same group. This is concurrent to findings from other
studies [25]. that hypothesized the relation to the worse
social and psychological factors among the elderly and
women [25] Therefore, these groups might benefit from
healthier lifestyle, better health care, and social support.
Considerations in interpretation, limitations,
and strength
Life expectancies reported in this study need to be inter-
preted with caution. It should not be extrapolated as the
numbers of years left to live for CRC patients in general. The
survivors that formed the cohort in this study consisted of
mainly patients who were diagnosed in the study period: year
2005–2009 (49 %, whereas 33 and 21 % were diagnosed in
1998–2004 and 1975–1997, respectively). Mortality early
after cancer diagnosis is high [17]. As seen in our analysis,
those followed only for 5 years had a substantial shorter life
expectancy as those who had a longer follow-up. In our
sensitivity analysis (Appendix 2), we showed that including
patients with longer follow-up does not change our final
conclusion. In addition, we also included patients in terminal
stage who contributed to the very high mortality and very few
person years (see Fig. 1). Although these patients only
contributed to 6 % of the total person years in the cohort, they
contributed to 27 % of the total deaths. These two factors
mentioned above account for the generally low life expec-
tancy (when all stages were aggregated in a single life
expectancy estimate) reported in our study.
Several limitations should be taken into account after
reading our findings. First, our result relied solely on direct
assessments of health states measured with questionnaires.
This approach assumes that individuals use the same
response thresholds in reporting [26]. However, following a
cancer diagnosis, patients experience a dramatic change that
may alter their internal values, leading to a shift in response
for the assessment of health [27]. So the group that was
expected to have poor health or disability reported similar or
better health than the group who is expected to be better off.
Finally, we only used three items from the whole domains in
quality of life in measuring our outcome. In Appendix 3, we
assessed the impact of including emotional domains into the
analysis which resulted in similar finding to our main anal-
ysis. Earlier studies have shown, although having compara-
ble QoL, colorectal cancer is experiencing long-lasting
specific symptoms such as fatigue, nausea/vomiting, pain,
insomnia, and appetite loss [28]. Smaller subgroups of
patients, for example those living with stoma have also
reported poorer quality of life [12]. Thus, limitations in these
other areas could have been masked.
By using a population-based data, we ensured com-
pleteness and also reliability in the construction of the life
table and its result. In this study, we incorporated patients’
survival and quality of life information in one estimate
(HLE and DFLE). Assessment of patients’ prognosis after
cancer diagnosis had mostly been based either on survival
time or on quality of life. Having them both in a single
measure will ease the valuation of life expectancy after
diagnosis and useful for patients’ information or guidelines
in clinical decision.
Conclusions
Our finding suggests high proportion of healthy life
expectancy among CRC survivors. All the more, for some
groups of CRC survivors, the proportion of HLE exceeds
that of the general population, highlighting the importance
of early detection. Survivors of stage IV CRC are most
likely to report poor health and spent a large proportion of
their remaining life in ill health, highlighting the
Cancer Causes Control (2012) 23:1421–1428 1427
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importance of early detection and palliative care. Survivors
with comorbidity, elderly, women, and lower socioeco-
nomic class also reported high prevalence of poor health
and disability. This highlights the value of healthier life-
style, and improvement in social and health care policies.
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